Background SOBERANA 02 is a COVID-19 vaccine based on SARS-CoV-2 recombinant
RBD conjugated to tetanus toxoid (TT). SOBERANA Plus antigen is dimeric-RBD. Here we …

Background SOBERANA 02 has been evaluated in phase I and IIa studies comparing
homologous versus heterologous schedule (this one, including SOBERANA Plus). Here, we …

We have developed a single process for producing two key COVID-19 vaccine antigens:
SARS-CoV-2 receptor binding domain (RBD) monomer and dimer. These antigens are featured …

Background We report results of immunogenicity, safety and reactogenicity of SOBERANA
02 in a two-dose or three-dose heterologous scheme in adults in a phase IIb clinical trial. …

… Maria Eugenia Toledo-Romani; Leslihana Verdecia Sanchez; Meybis Rodriguez
Gonzalez; Laura Rodriguez Noda; Carmen Valenzuela Silva; Beatriz Paredes Moreno; …

Introducción: El control de la pandemia global de COVID-19 depende, entre otras medidas,
del desarrollo de vacunas preventivas contra el SARS-CoV-2. La infección del virus está …

The COVID-19 pandemic has caused a large number of diseases worldwide. There are few
vaccines to constrain this disease and the value of them is high. In this sense, the antigens …

Infliximab is a mouse/human chimeric IgG1 monoclonal antibody which recognizes the
proinflammatory cytokine, tumor necrosis factor α (TNFα), and inhibits receptor interactions, …

… Daidée Montes de Oca-García1,2* ORCID: https://orcid.org/0009-0007-9056-2638 Sum
Lai Lozada-Chang1 ORCID: https://orcid.org/0000-0002-1688-140X Tammy Boggiano-Ayo1 …

The high prices of biopharmaceuticals or biologics used in the treatment of many diseases
limit the access of patients to these novel therapies. One example is the monoclonal antibody …